Jones Trading Upgrades Spyre Therapeutics to Buy, Announces $64 Price Target

Benzinga · 12/01 13:17
Jones Trading analyst Debanjana Chatterjee upgrades Spyre Therapeutics (NASDAQ:SYRE) from Hold to Buy and announces $64 price target.